Primarily, ischemic stroke patients are treated with alteplase (tissue plasminogen activator, tPA) across the region; however, two sites, one in NS and the other in PE, participated in the ACT (Alteplase compared to Tenecteplase) trial (Menon et al., 2022); therefore, some patients were treated with Tenecteplase (TNK) in this region. This evidence concerns the gene PLAT and ischemic stroke.